Positive Phase 2 Explore-CKD results for lorundrostat; primary endpoint met

Mineralys Therapeutics, Inc.

Lorundrostat 25 mg reduced systolic BP by 9.3 mmHg (–7.5 mmHg placebo-adjusted, p=0.0024) in hypertensive CKD patients.
UACR reduction of 31% (–25.6% placebo-adjusted, p=0.0015) suggests renal protective potential.
Favorable safety profile: 3% SAEs (lorundrostat), 5% hyperkalemia rate; 3% discontinuation due to TEAEs.
Data augment pivotal Phase 3 Launch-HTN and other trials; company plans NDA submission including these results.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.